Business
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUS...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n SUNNYVALE, Calif.\n \n \n ,\n \n \n Aug. 21, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, today announced a collaboration with a Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs).\n \n \n \n \n \n \n \n \n \n Willow's collaboration partner recognized the need to employ more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste and sought Willow's expertise in developing and scaling key ingredients. The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale. The development phase of this funded collaboration is expected to last approximately two months. Due to the competitive nature of the targeted ingredient applications, the partner's name and further information is not being disclosed at this time.\n \n \n \"We are honored to have been selected by such a forward-thinking biopharmaceutical company to jointly explore innovative pathways toward the development of sustainably sourced intermediates and APIs,\" said Dr.\n \n Chris Savile\n \n , Willow's President & CEO. \"If successful, we believe that by leveraging biobased routes, these ingredients essential for human health can be made more broadly available while providing a solution for overseas supply chain issues that can increase cost and potentially create shortages.\"\n \n \n This agreement represents the 5\n \n th\n \n new development agreement executed by Willow in 2023, with a robust pipeline of other potential colla...